Overview of Hematopoietic Disorders

Hematopoietic disorders are diseases that affect the blood and blood-forming organs. They involve the production of blood cells by hematopoietic stem cells in the bone marrow, lymph nodes, and spleen. Blood cells include red blood cells (carry oxygen and carbon dioxide), white blood cells (fight infection and clear foreign substances), and platelets (promote blood clotting). Hematopoietic disorders can be classified into three categories: hematopoietic stem cell defects (reduced number or function of hematopoietic stem cells), blood cell abnormalities (abnormal number or function of one or more types of blood cells), and blood clotting abnormalities (impaired number or function of platelets or clotting factors). The causes of hematopoietic disorders may include gene mutations, chromosomal abnormalities, environmental factors, immune system disorders, and so on. Gene mutations are changes in the DNA sequence that affect the proteins involved in blood cell development or function. Chromosomal abnormalities are changes in the number or structure of chromosomes that result in gene loss or duplication. Environmental factors are external influences that damage DNA or affect DNA repair mechanisms. Immune system disorders are abnormal reactions of the immune system to self-tissues or organs. The symptoms of hematopoietic disorders may include anemia (reduced oxygen delivery), bleeding (impaired blood clotting), infection (reduced immunity), tumor (abnormal cell growth), immune deficiency (reduced immunity), and so on.

Hematopoietic Stem Cell Defects

Hematopoietic stem cell defects are a type of hematopoietic disorder that affects the number or function of hematopoietic stem cells (HSCs), which are the source of all blood cells. HSCs are located in the bone marrow and can differentiate into various types of blood cells, such as red blood cells, white blood cells, and platelets. HSCs can also self-renew to maintain a constant pool of stem cells.

One example of hematopoietic stem cell defects is Fanconi anemia (FA), which is a rare inherited disorder caused by mutations or deletions of genes that are involved in DNA repair. FA affects the function and survival of HSCs, leading to bone marrow failure and pancytopenia. FA patients also have congenital malformations such as skin pigmentation, microcephaly, limb defects, and so on. FA patients have a high risk of developing leukemia, myelodysplastic syndrome, and solid tumors. The diagnosis of FA is based on clinical features, blood tests, bone marrow examination, cytogenetic analysis, and molecular genetic testing. Blood tests can reveal the number and morphology of blood cells and the level of hemoglobin and clotting factors. A bone marrow examination can reveal the number and morphology of HSCs and their progenitors. Cytogenetic analysis can reveal chromosomal abnormalities that affect HSCs. Molecular genetic testing can identify specific gene mutations or deletions that cause FA. The treatment of FA is mainly based on hematopoietic stem cell transplantation (HSCT), which involves replacing the defective HSCs with healthy HSCs from a compatible donor. HSCT can restore normal blood cell production and immunity and cure some types of hematopoietic disorders. Other treatment options may include androgen therapy (such as dexamethasone or oxymetholone), growth factor therapy (such as recombinant human erythropoietin or recombinant human granulocyte colony-stimulating factor), blood transfusion, and so on. The gene therapy of FA is currently under clinical trials, which involves introducing normal FANCA genes into the patient’s own or donor’s HSCs, and then transplanting these gene-corrected HSCs to the patient. The aim of gene therapy is to achieve a permanent cure for FA by restoring normal DNA repair function in HSCs.

Blood Cell Abnormalities

Hematopoietic disorders affect blood or blood-forming cells, including anemia, leukemia, lymphoma, myelodysplastic syndrome, etc. These diseases may be inherited or acquired and may cause abnormal numbers or functions of red blood cells, white blood cells, or platelets in the blood.

Anemia is a common hematopoietic disorder that refers to the low level of oxygen-carrying protein (hemoglobin) in the blood, causing hypoxia in the body. Anemia has many types, some of which are related to genetic factors, such as thalassemia, sickle cell anemia, Diamond-Blackfan anemia, etc. These types of anemia are usually caused by gene mutations that cause abnormal structures or functions of red blood cells or hemoglobin. The main symptoms of anemia include fatigue, dizziness, palpitations, and dyspnea. The treatment plan for anemia depends on its type and severity and generally includes blood transfusion, drug therapy, and bone marrow transplantation. Gene therapy is an emerging treatment method that aims to restore normal red blood cell or hemoglobin function by repairing or replacing abnormal genes. Currently, gene therapy has shown effectiveness and safety in some clinical trials for some types of anemia (such as sickle cell anemia and beta-thalassemia).

Leukemia is a malignant hematopoietic disorder that refers to the abnormal proliferation of white blood cells in the bone marrow and the invasion of other organs and tissues. Leukemia has many types, which can be divided into acute and chronic according to the composition and development speed of white blood cells. Acute leukemia refers to the rapid proliferation of abnormal white blood cells, which squeeze out normal hematopoietic cells in the bone marrow and cause symptoms such as anemia, infection, and bleeding. The main types of acute leukemia are acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). The cause of acute leukemia is unknown but may be related to genetic, environmental, chemical, and radiation factors. Chronic leukemia refers to the slow proliferation of abnormal white blood cells, which cause excessive white blood cells in the blood and symptoms such as hepatosplenomegaly, fatigue, and weight loss. The main types of chronic leukemia are chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). The cause of chronic leukemia is unknown but may be related to genetic, age, and gender factors. The treatment plan for acute and chronic leukemia mainly includes drug therapy, targeted therapy, immunotherapy, and bone marrow transplantation. Gene therapy is an emerging treatment method that aims to control or eliminate leukemia cells or enhance the resistance of normal cells by repairing or replacing abnormal genes. Currently, gene therapy has shown effectiveness and safety in some clinical trials for some types of acute and chronic leukemia.

Blood Clotting Abnormalities

Blood clotting abnormalities are conditions that affect the normal function of the blood and may cause excessive bleeding or clot formation. Blood clotting abnormalities can be divided into bleeding disorders and thrombotic disorders, depending on their causes and manifestations. According to their etiology and mechanism, blood coagulation abnormalities can be divided into two categories: acquired and hereditary. Acquired blood coagulation abnormalities are caused by acquired factors affecting the normal blood coagulation balance, leading to coagulation dysfunction or hyperfibrinolysis. The common ones are DIC, liver disease, vitamin K deficiency, anticoagulant drug overdose, severe infection, and malignant tumor. Such diseases usually occur in adulthood with extensive bleeding or thrombosis, such as skin petechiae, mucous membrane bleeding, internal bleeding, deep vein thrombosis, and pulmonary embolism, and can also be life-threatening. Hereditary blood coagulation abnormalities are due to gene mutations that lead to the deficiency or dysfunction of coagulation factors or fibrinolytic factors. Common examples are hemophilia, von Willebrand disease, congenital fibrinogen deficiency, congenital anticoagulation Blood enzyme deficiency, etc. Such diseases usually have a bleeding tendency in childhood, such as skin and mucous membrane bleeding, joint muscle bleeding, and severe cases can be life-threatening. Among them, hemophilia is a common hereditary bleeding disorder caused by gene defects on the X chromosome that result in a lack or dysfunction of clotting factors VIII or IX. Hemophilia patients mainly show repeated spontaneous or minor trauma bleeding that is difficult to stop. The common bleeding sites are joints, muscles, skin, mucous membranes, and so on. Severe cases may also have life-threatening situations such as intracranial hemorrhage, chest hemorrhage, abdominal hemorrhage, and so on.

The main method of treating and preventing hemophilia is to supplement the lacking clotting factor by intravenous injection of humanized recombinant or concentrated, purified human-derived clotting factor VIII or IX preparations. In addition, some hemostatic drugs can be used to control mild to moderate bleeding, such as tranexamic acid, deoxyribonuclease, pituitary posterior lobe hormone, and so on. At the same time, some possible complications need to be prevented and treated, such as joint deformity, infection, depression, and so on. Patients and family members also need to be trained and educated on how to identify and deal with bleeding events, how to self-inject and treat at home, and how to receive psychological support and social resources.

Gene therapy is a method of correcting genetic defects and restoring normal function by transferring normal genes into the patient's body. There have been some trials of gene therapy for type A and type B patients, with some results. For example, in a trial for type A patients, a non-toxic recombinant adenovirus-associated virus type 5 vector (AAV5) was used to transfer the normal F8 gene into the patient's liver cells, enabling them to synthesize sufficient amounts of clotting factor VIII and maintain stable levels for more than three years. This method may provide a safe, effective, durable, and convenient treatment option for type A patients.

In addition to gene therapy, there are other new treatments under development, such as monoclonal antibodies, small molecule drugs, stem cell transplantation, etc. These approaches aim to improve hemostasis and quality of life in patients through mechanisms such as improving coagulation factor activity, inhibiting plasminogen activator inhibitor (TAFI), or enhancing endothelial cell function. However, these methods still need more clinical trials to prove their safety and efficacy, and to solve some existing problems, such as immune tolerance, side effects, cost, etc.

References

1. Bogeska R, et al. Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging. Cell Stem Cell. 2022 Aug 4;29(8):1273-1284.e8.
2. Anurogo D, et al. Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing. Int J Mol Sci. 2021 Jun 10;22(12):6275.
3. Galvin A, et al. Cell Cycle Analysis of Hematopoietic Stem and Progenitor Cells by Multicolor Flow Cytometry. Curr Protoc Cytom. 2019 Jan;87(1):e50.
4. Peake JD, et al. Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair. Hum Genet. 2022 Dec;141(12):1811-1836.
5. Fiesco-Roa MO, et al. Genotype-phenotype associations in Fanconi anemia: A literature review. Blood Rev. 2019 Sep;37:100589.
6. Dufour C, et al. Modern management of Fanconi anemia. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):649-657.
7. Ferrari G, et al. Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet. 2021;22(4):216-234.
8. Al-Saif AM. Gene therapy of hematological disorders: current challenges. Gene Ther. 2019;26(8):296-307.
9. Al-Saif AM, et al. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. Nat Commun. 2022;13(1):1-14.
10. Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):1-8.
11. Dolan G, et al. Principles of care for acquired hemophilia. Eur J Haematol. 2021 Jun;106(6):762-773.
12. Klamroth R, et al. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Hum Gene Ther. 2022 Apr;33(7-8):432-441.